Chembio Diagnostics (CEMI) 10-K 7 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 03, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Chembio Diagnostics, Inc.
Entity Central Index Key	1,092,662
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 76,422,282
Entity Common Stock, Shares Outstanding		12,299,122
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 10,554,464	$ 5,376,931
Accounts receivable, net of allowance for doubtful accounts of $52,000 and $52,000 at December 31, 2016 and 2015, respectively	3,383,729	2,422,971
Inventories	3,335,188	3,578,025
Prepaid expenses and other current assets	840,145	1,256,879
TOTAL CURRENT ASSETS	18,113,526	12,634,806
FIXED ASSETS, net of accumulated depreciation	1,709,321	2,374,308
OTHER ASSETS:
Deferred tax asset, net of valuation allowance	0	5,467,143
License agreements, net of current portion	0	100,000
Deposits on manufacturing equipment	31,900	30,918
Deposits and other assets	720,489	209,169
TOTAL ASSETS	20,575,236	20,816,344
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	3,013,133	2,801,432
Deferred revenue	392,517	353,406
TOTAL CURRENT LIABILITIES	3,405,650	3,154,838
OTHER LIABILITIES:
TOTAL LIABILITIES	3,405,650	3,154,838
STOCKHOLDERS' EQUITY:
Preferred stock - 10,000,000 shares authorized; none outstanding	0	0
Common stock - $.01 par value; 100,000,000 shares authorized, 12,026,847 and 9,628,248 shares issued and outstanding for 2016 and 2015, respectively	120,268	96,282
Additional paid-in capital	60,721,783	47,890,642
Accumulated deficit	(43,672,465)	(30,325,418)
TOTAL STOCKHOLDERS' EQUITY	17,169,586	17,661,506
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 20,575,236	$ 20,816,344

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS:
Accounts receivable, allowance for doubtful accounts	$ 52,000	$ 52,000
STOCKHOLDERS' EQUITY:
Preferred stock - shares authorized (in shares)	10,000,000	10,000,000
Preferred stock - shares outstanding (in shares)	0	0
Common stock - par value (in dollars per share)	$ 0.01	$ 0.01
Common stock - shares authorized (in shares)	100,000,000	100,000,000
Common stock - shares issued (in shares)	12,026,847	9,628,248
Common stock - shares outstanding (in shares)	12,026,847	9,628,248

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
REVENUES:
Net sales	$ 13,680,107	$ 21,886,688	$ 25,949,769
License and royalty revenue	449,685	52,753	23,257
R&D, milestone and grant revenue	3,739,049	2,316,044	1,672,258
TOTAL REVENUES	17,868,841	24,255,485	27,645,284
Cost of product sales	9,417,505	13,768,658	16,831,261
GROSS MARGIN	8,451,336	10,486,827	10,814,023
OPERATING EXPENSES:
Research and development expenses	8,427,554	6,377,839	4,832,537
Selling, general and administrative expenses	7,595,559	7,663,035	7,531,739
TOTAL OPERATING EXPENSES	16,023,113	14,040,874	12,364,276
LOSS FROM OPERATIONS	(7,571,777)	(3,554,047)	(1,550,253)
OTHER INCOME (EXPENSE):
Other expense	0	(4,814)	(5,707)
Interest income	25,548	2,412	5,839
Interest expense	0	(836)	0
TOTAL OTHER INCOME (EXPENSE)	25,548	(3,238)	132
LOSS BEFORE INCOME TAXES (BENEFIT)	(7,546,229)	(3,557,285)	(1,550,121)
Income tax provision (benefit)	5,800,818	(1,160,243)	(412,918)
NET LOSS	$ (13,347,047)	$ (2,397,042)	$ (1,137,203)
Basic loss per share (in dollars per share)	$ (1.26)	$ (0.25)	$ (0.12)
Diluted loss per share (in dollars per share)	$ (1.26)	$ (0.25)	$ (0.12)
Weighted average number of shares outstanding, basic (in shares)	10,622,331	9,626,028	9,530,320
Weighted average number of shares outstanding, diluted (in shares)	10,622,331	9,626,028	9,530,320

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2013	$ 93,248	$ 46,875,027	$ (26,791,173)	$ 20,177,102
Balance (in shares) at Dec. 31, 2013	9,324,783
Options:
Exercised	$ 2,864	234,299	0	$ 237,163
Exercised (in shares)	286,356			286,356
Stock option compensation	$ 0	447,100	0	$ 447,100
Net loss			(1,137,203)	(1,137,203)
Balance at Dec. 31, 2014	$ 96,112	47,556,426	(27,928,376)	19,724,162
Balance (in shares) at Dec. 31, 2014	9,611,139
Options:
Exercised	$ 170	(170)	0	$ 0
Exercised (in shares)	17,109			17,109
Stock option compensation	$ 0	334,386	0	$ 334,386
Net loss	0	0	(2,397,042)	(2,397,042)
Balance at Dec. 31, 2015	$ 96,282	47,890,642	(30,325,418)	17,661,506
Balance (in shares) at Dec. 31, 2015	9,628,248
Common Stock:
New Stock from Offering	$ 23,000	12,470,398	0	12,493,398
New Stock from Offering (in shares)	2,300,000
Options:
Exercised	$ 986	56,589	0	$ 57,575
Exercised (in shares)	98,599			98,599
Stock option compensation	$ 0	304,154	0	$ 304,154
Net loss	0	0	(13,347,047)	(13,347,047)
Balance at Dec. 31, 2016	$ 120,268	$ 60,721,783	$ (43,672,465)	$ 17,169,586
Balance (in shares) at Dec. 31, 2016	12,026,847

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Cash received from customers and grants	$ 16,947,194	$ 30,174,083	$ 23,898,516
Cash paid to suppliers and employees	(23,677,476)	(28,382,681)	(27,724,654)
Interest received	25,548	2,412	5,839
Interest paid	0	(836)	0
Net cash provided by (used in) operating activities	(6,704,734)	1,792,978	(3,820,299)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of license	0	(550,000)	0
Deposit for investment in RVR	(550,000)	0	0
Acquisition of and deposits on fixed assets	(118,706)	(480,585)	(1,452,601)
Net cash used in investing activities	(668,706)	(1,030,585)	(1,452,601)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from option and warrant exercises	57,575	0	237,163
Proceeds from Issuance of Common Stock, net	12,493,398	0	0
Proceeds from credit line	0	700,000	0
Payment of credit line	0	(700,000)	0
Net cash provided by financing activities	12,550,973	0	237,163
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	5,177,533	762,393	(5,035,737)
Cash and cash equivalents - beginning of the period	5,376,931	4,614,538	9,650,275
Cash and cash equivalents - end of the period	10,554,464	5,376,931	4,614,538
RECONCILIATION OF NET LOSS TO NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES:
Net Loss	(13,347,047)	(2,397,042)	(1,137,203)
Adjustments:
Depreciation and amortization	1,139,228	1,372,563	739,297
Provision for (benefit from) deferred taxes	5,800,818	(1,170,969)	(403,375)
Provision of (recovery of) doubtful accounts	0	0	28,000
Share based compensation	304,154	334,386	447,100
Changes in assets and liabilities:
Accounts receivable	(960,758)	5,915,918	(3,774,768)
Inventories	242,837	60,274	(449,573)
Prepaid expenses and other current assets	(136,258)	(190,960)	32,906
Deposits and other assets	1,480	0	(279,223)
Accounts payable and accrued liabilities	211,701	(2,144,598)	636,540
Customer deposits and deferred revenue	39,111	13,406	340,000
Net cash provided by (used in) operating activities	(6,704,734)	1,792,978	(3,820,299)
Supplemental disclosures for non-cash investing and financing activities:
Deposits on manufacturing equipment transferred to fixed assets	$ 0	$ 20,017	$ 603,627

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2016
DESCRIPTION OF BUSINESS [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 — DESCRIPTION OF BUSINESS: Chembio Diagnostics, Inc. and its subsidiary, Chembio Diagnostic Systems, Inc. (collectively, the "Company" or "Chembio"), develop, manufacture, and market rapid diagnostic tests that detect infectious diseases. The Company's main lateral flow products are three rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, two of which were approved by the FDA in 2006; the third is sold for export only. Lateral Flow Rapid HIV tests represented nearly 58% of the Company's product revenues in 2016. The Company's products based on its patented DPP® platform represented approximately 40% of the Company's product revenues in 2016. The Company also has other rapid tests that together represented approximately 2% of sales in 2016. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. Chembio's products are sold under the Company's STAT-PAK®, SURE CHECK®, STAT VIEW® or DPP® registered trademarks, or under the private labels of its marketing partners. All of the Company's products that are currently being developed are based on its patented Dual Path Platform (DPP®), which is a unique diagnostic point-of-care platform that has certain advantages over lateral flow technology. In December 2012, the Company received FDA approval for its DPP® HIV 1/2 Assay for the detection of HIV antibodies in saliva, whole blood, serum and plasma samples, which was CLIA-Waived in October 2014.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES: (a) Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. (b) Use of Estimates: The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make assumptions and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods covered thereby. Actual results could differ from these estimates. Judgments and estimates of uncertainties are required in applying the Company's accounting policies in certain areas. The following are some of the areas requiring significant judgments and estimates: determinations of the useful lives of assets, estimates of allowances for doubtful accounts, inventory reserves, stock-based compensation and deferred tax assets. (c) Fair Value of Financial Instruments: The carrying value for cash and cash equivalents, accounts receivable and accounts payable, approximate fair value because of the immediate or short-term maturity of these financial instruments. (d) Statements of Cash Flows: For purposes of the statements of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. (e) Concentrations of Credit Risk: Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments and trade receivables. The Company places its temporary cash instruments with well-known financial institutions and, at times, may maintain balances in excess of the FDIC insurance limit. The Company monitors the credit ratings of the financial institutions to mitigate this risk. Concentration of credit risk with respect to trade receivables is principally mitigated by the Company's ability to obtain letters of credit from certain foreign customers, and its diverse customer base both in number of customers and geographic locations. (f) Inventories: Inventories, consisting of material, labor and manufacturing overhead, are stated at the lower of cost or market. Cost is determined on the first-in, first-out method. (g) Fixed Assets: Fixed assets are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which range from three to seven years. Leasehold improvements are amortized over the useful life of the asset or the lease term, whichever is shorter. Deposits paid for fixed assets are capitalized and not depreciated until the related asset is placed in service. (h) License Agreements: In February 2008, the Company entered into a sublicense agreement for which it had initially recorded an asset of $1,000,000. This asset is being expensed over an estimated economic life of ten years, based on the expected lifespan of our then current HIV products. The current portion of this asset is $100,000 as of December 31, 2016 and 2015 and is reported in prepaid expenses and other current assets. The long-term portion as of December 31, 2016 and 2015 is $- and $100,000, respectively and is reflected in other assets on the consolidated balance sheet. In January 2015, the Company entered into a sublicense agreement for which it had initially recorded an asset of $400,000. This asset is being expensed over the life of the patent of 22 months. The current portion of this asset is $- and $181,818 as of December 31, 2016 and 2015, respectively and is reported in prepaid expenses. The long-term portion as of December 31, 2016 and 2015 is $- and $-, respectively and is reflected in other assets on the consolidated balance sheet. In August 2015, the Company entered into a sublicense agreement for which it had initially recorded an asset of $100,000. This asset is being validated and will be expensed over the estimated economic life of the product(s) which will utilize this sublicense. The current portion of this asset is $100,000 as of December 31, 2016 and 2015 and is reported in prepaid expenses and other current assets. The long-term portion of this asset is $- as of December 31, 2016 and 2015. Amortization expenses for the licenses above for the years ended December 31, 2016, 2015 and 2014 were $357,000, $479,000 and $122,000. (i) Impairment of Long-Lived Assets and Intangible Assets Long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. We believe that the carrying values of our long-lived tangible and intangible assets were realizable at December 31, 2016 and 2015, respectively. (j) Revenue Recognition: The Company recognizes revenue for product sales in accordance with ASC 605, revenue is recognized when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is fixed and determinable, and collectability is reasonably assured. Revenue typically is recognized at time of shipment. Sales are recorded net of discounts, rebates and returns. For certain contracts, the Company recognizes revenue from non-milestone contracts and grant revenues when earned. Grants are invoiced after expenses are incurred. Revenues from projects or grants funded in advance are deferred until earned. The Company follows Financial Accounting Standards Board ("FASB") Accounting Standards for the recognition of revenue under the milestone method. The Company applies the milestone method of revenue recognition for certain collaborative research projects defining milestones at the inception of the agreement. (k) Research and Development: Research and development (R&D) costs are expensed as incurred. (l) Stock-Based Compensation: Stock-based compensation expense is calculated using the Black-Scholes valuation model based on awards ultimately expected to vest, reduced for forfeitures, and expensed on a straight-line basis over the requisite service period of the grant. (m) I ncome Taxes: The Company accounts for income taxes under an asset and liability approach which recognizes deferred tax assets and liabilities based on the difference between the financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company follows a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The guidance relates to, among other things, classification, accounting for interest and penalties associated with tax positions, and disclosure requirements. Any interest and penalties accrued related to uncertain tax positions will be recorded in tax expense. The Company assesses the realizability of its net deferred tax assets on an annual basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, the Company would reduce the net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of net operating loss carryforwards. (n) Loss Per Share The following weighted average shares were used for the computation of basic and diluted earnings per share: For the years ended December 31, 2016 December 31, 2015 December 31, 2014 Basic 10,622,331 9,626,028 9,530,320 Diluted 10,622,331 9,626,028 9,530,320 Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share for the year ended December 31, 2016, 2015 and 2014 reflects the potential dilution from the exercise or conversion of other securities into common stock, if dilutive. The following securities, presented on a common share equivalent basis, have been used in the diluted per share computations: For the years ended December 31, 2016 December 31, 2015 December 31, 2014 1999, 2008 and 2014 Plan Stock Options - - - There were 600,549, 658,631 and 798,475 options and warrants outstanding as of December 31, 2016, 2015 and 2014, respectively, which were not included in the calculation of diluted income per share for the years ended because their effect would have been anti-dilutive. (o) Recent Accounting Pronouncements Affecting the Company: In May 2014, the FASB issued Accounting Standards Update No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09"), which supersedes nearly all existing revenue recognition guidance under accounting principles generally accepted in the United States ("U.S. GAAP"). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018. The Company has conducted a preliminary analysis of its sales contracts which are based on the shipment of goods to the customer, and currently this new accounting standard will not have a material impact on its consolidated financial statement for our sales contracts. The Company has conducted a preliminary analysis of its current R&D contracts which are currently based on "as expenses are incurred" basis, and currently this new accounting standard will not have a material impact on its consolidated financial statement for our current R&D contracts. In November 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-17, Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and will require an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the current guidance, entities are required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. This guidance will be effective for Chembio beginning in 2018, with early adoption permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update ("ASU") 2016-02, which amends the ASC and creates Topic 842, Leases. Topic 842 will require lessees to recognize lease assets and lease liabilities for those leases classified as operating leases under previous US GAAP on the balance sheet. This guidance is effective for annual periods beginning after December 15, 2018 and early adoption is permitted. We are in the initial stages of evaluating the effect of the standard on our financial statements and will continue to evaluate. While not yet in a position to assess the full impact of the application of the new standard, the Company expects that the impact of recording the lease liabilities and the corresponding right-to-use assets will have a significant impact on its total assets and liabilities with a minimal impact on equity. In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which will change certain aspects of accounting for share-based payments to employees. ASU 2016-09 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2016. The Company is currently in the initial stages of evaluating the impact of the provisions of ASU 2016-09. We are still evaluating this standard and currently the Company does not believe this new accounting standard will have a material impact on its consolidated financial statement.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2016
INVENTORIES [Abstract]
INVENTORIES	NOTE 3 — INVENTORIES: Inventories consist of the following at: December 31, 2016 December 31, 2015 Raw materials $ 1,824,248 $ 2,248,371 Work in process 535,320 370,340 Finished goods 975,620 959,314 $ 3,335,188 $ 3,578,025

FIXED ASSETS

FIXED ASSETS	12 Months Ended
	Dec. 31, 2016
FIXED ASSETS [Abstract]
FIXED ASSETS	NOTE 4 — FIXED ASSETS: Fixed assets consist of the following at: December 31, 2016 December 31, 2015 Machinery and equipment $ 3,962,051 $ 3,862,698 Furniture and fixtures 437,962 436,588 Computer and telephone equipment 343,167 326,170 Leasehold improvements 2,012,945 2,012,945 6,756,125 6,638,401 Less accumulated depreciation and amortization (5,046,804 ) (4,264,093 ) $ 1,709,321 $ 2,374,308 There were no capital leases at the end of December 31, 2016. Fixed assets at December 31, 2016 also include $199,921 in equipment, which has been delivered and set-up but is undergoing validation and as such is currently not being depreciated. Depreciation expense for the 2016, 2015 and 2014 years aggregated $782,711, $893,305 and $616,943, respectively. As of December 31, 2016 and 2015, the Company had paid deposits on various pieces of equipment aggregating $31,900 and $30,918, respectively.

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2016
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	NOTE 5 — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES: Accounts payable and accrued liabilities consist of the following at: December 31, 2016 December 31, 2015 Accounts payable – suppliers $ 1,437,290 $ 1,260,520 Accrued commissions 221,982 129,192 Accrued royalties / license fees 352,660 732,301 Accrued payroll 167,575 146,962 Accrued vacation 289,587 244,810 Accrued bonuses 282,500 177,700 Accrued expenses – other 261,539 109,947 TOTAL $ 3,013,133 $ 2,801,432

DEFERRED RESEARCH AND DEVELOPME

DEFERRED RESEARCH AND DEVELOPMENT REVENUE	12 Months Ended
	Dec. 31, 2016
DEFERRED RESEARCH AND DEVELOPMENT REVENUE [Abstract]
DEFERRED RESEARCH AND DEVELOPMENT REVENUE	NOTE 6 — DEFERRED RESEARCH AND DEVELOPMENT REVENUE: The Company recognizes income from R&D milestones when those milestones are reached and non-milestone contracts and grants when earned. Grants are invoiced after expenses are incurred. Any projects or grants funded in advance are deferred until earned. As of December 31, 2016 and 2015, there were $392,517 and $353,406 unearned advanced revenues, respectively.

TERM NOTE, REVOLVING DEMAND NOT

TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE	12 Months Ended
	Dec. 31, 2016
TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE [Abstract]
TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE	NOTE 7 — TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE: On April 30, 2013, the Company entered into a new demand loan agreement ("Demand Note") with HSBC Bank, USA ("HSBC"). The Demand Note allowed the Company to draw on the line from time to time an amount up to an aggregate of $2,000,000 outstanding at any one time. The accrued interest on the Demand Note was payable monthly at an interest rate equal to one-quarter percent above prime per annum. The Company could repay any or all of the principal balance outstanding at any time. This was a demand note for which the bank lender could demand repayment of the entire loan, with accrued interest, at any time. The loan was subject to annual reviews, as well as an annual 30-day clean-up, during which there could be no amounts outstanding. In January 2016 HSBC notified the Company that it could no longer extend the credit and the Demand Note was cancelled. The Security Agreement, related to the Demand Note, contained covenants that placed restrictions on the Company's operations, including covenants relating to mergers, debt restrictions, capital expenditures, tangible net worth, net profit, leverage, fixed charge coverage, employee loan restrictions, distribution restrictions (common stock and preferred stock), dividend restrictions, restrictions on lease payments to affiliates, restrictions on changes in business, asset sale restrictions, restrictions on acquisitions and intercompany transactions, and restrictions on fundamental changes in the Company and in its business. The Company currently maintains its operating, payroll, and primary cash accounts at HSBC.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2016
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 8 The (benefit from) provision for income taxes for the years ended December 31, 2016 and 2015, is comprised of the following: 2016 2015 2014 Current Federal $ - $ - $ (16,119 ) State - 10,726 6,576 Total current (benefit) provision - 10,726 (9,543 ) Deferred Federal 5,778,185 (1,171,865 ) (449,452 ) State 22,633 896 46,077 Total deferred (benefit) provision 5,800,818 (1,170,969 ) (403,375 ) Total (benefit) provision $ 5,800,818 $ (1,160,243 ) (412,918 ) The Company had an ownership change as described in Internal Revenue Code Sec. 382 during 2004 ("2004 change"). As a result, the Company's net operating losses prior to the 2004 change of $5,832,516 were subject to an annual limitation of $150,608 and for the first five (5) years are entitled to a BIG (Built-In-Gains) of $488,207 per year. These net operating losses expire in 2018 through 2024. The Company had a second ownership change during 2006 ("2006 change"). The net operating losses incurred between the 2004 change and the 2006 change of $8,586,861 were subject to an annual limitation of $1,111,831 and for the first five (5) years are entitled to a BIG of $1,756,842 per year. These net operating losses expire in 2018 through 2028. After applying the above limitations, at December 31, 2016, the Company has post-change net operating loss carry-forwards of approximately $21,960,362 which expire between 2020 and 2036. In addition the Company has research and development tax credit carryforwards of approximately $1,461,351 for the year ended December 31, 2016, which expire between 2025 and 2036. 2016 2015 Current assets Inventory reserves $ 253,380 $ 242,532 Accrued expenses 53,140 91,143 Current deferred tax assets 306,520 333,675 Less valuation allowances (306,520 ) - Net current deferred asset $ - $ 333,675 Noncurrent assets Net operating loss carry-forwards $ 7,487,937 $ 5,365,401 Research and development credit 1,461,351 1,518,414 Other credits 97,339 97,339 Depreciation 31,285 (206,150 ) Other 292,556 210,553 Noncurrent deferred tax assets 9,370,468 6,985,557 Less valuation allowances (9,370,468 ) (1,518,414 ) Net noncurrent deferred tax assets $ - $ 5,467,143 A reconciliation of the Federal statutory rate to the effective rate applicable to income (loss) before income taxes is as follows: Year Ending December 31, 2016 2015 2014 Federal income tax at statutory rates (34.00)% (34.00)% (34.00)% State income taxes, net of federal benefit .21% 0.23% 0.28% Nondeductible expenses .57% 1.38% 4.54% Change in valuation allowance 114.81% 9.46% 9.47% Tax credits .00% (9.46)% (9.47)% Change in tax rates .00% 0.00% 1.96% Other .04% 0.34% 0.58% Income tax (benefit) 81.63% (32.05)% (26.64)% Interest and penalties, if any, related to income tax liabilities are included in income tax expense. As of December 31, 2016, the Company does not have a liability for uncertain tax positions. The Company files Federal and state income tax returns. Tax years for fiscal 2013 through 2015 are open and potentially subject to examination by the federal and state taxing authorities.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2016
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9 — STOCKHOLDERS' EQUITY: (a) Common Stock In August of 2016, the Company closed on an underwritten public offering of 2,300,000 shares of its common stock at $6.00 per share. The net proceeds of the offering, after deducting the underwriters' discounts and other offering expenses payable by the Company, was approximately $12,493,000. The Company intends to use the net proceeds for business expansion and working capital. During 2016, options to purchase 191,804 shares of the Company's common stock were exercised on a cashless basis into 98,599 shares of common stock at exercise prices ranging from $2.80 to $5.56 by surrendering options and shares of common stock already owned . During 2015, options to purchase 41,141 shares of the Company's common stock were exercised, either for cash or cashless, into 17,109 shares of common stock at exercise prices ranging from $2.16 to $3.60 by paying cash or surrendering options already owned. During 2014, options to purchase 318,750 shares of the Company's common stock were exercised, either for cash or cashless, into 286,356 shares of common stock at an exercise price of $1.04 by paying cash or surrendering options already owned (b) Preferred Stock The Company has 10,000,000 shares of preferred stock authorized and none outstanding. These shares can become issuable upon an approved resolution by the board of directors and the filing of a Certificate of Designation with the state of Nevada. (c) Options During the fourth quarter of 2016, the Company issued options to purchase 36,000 shares of common stock to a newly-hired president of the EMEA and APAC regions. The options are exercisable in three equal annual installments starting on the first anniversary of the date of issue. The options issued have an exercise price of $7.15 per share, which was the last traded price of the common stock on the day issued. The options expire five years from date of issue. During the second quarter of 2016 the Company issued options to purchase 46,875 shares of common stock to one of its directors pursuant to the Company's compensation policy for directors. The options become exercisable in five equal annual installments starting on the date of issue. The options issued have an exercise price of $8.860 per share, which was the last traded price of the common stock on the day issued. The options expire five years from date of issue. The Company entered into an employment agreement, effective as of March 5, 2016 (the "Employment Agreement"), with Javan Esfandiari to serve as the Company's Chief Scientific and Technical Officer, for an additional term of three years through March 5, 2019. Pursuant to the Employment Agreement, the Company issued to Mr. Esfandiari incentive and non-qualified stock options to purchase 60,000 shares of the Company's common stock. Of these stock options, options to purchase 20,000 shares vest on each of the first three anniversaries of March 11, 2016 which is the date on which the Employment Agreement was entered into. The exercise price for these options was to be equal to the trading price for the Company's common stock on March 11, 2016, which was $5.64 per share. Each option granted will expire and terminate, if not exercised sooner, upon the earlier to occur of (a) 30 days after termination of Mr. Esfandiari's employment with the Company or (b) the fifth anniversary of the effective date of the grant. During 2015, the Company did not issue options to purchase common stock. During the fourth quarter of 2014, the Company issued options to purchase 36,000 shares of common stock to a newly-hired vice-president of the Company. The options are exercisable in three equal annual installments starting on the first anniversary of the date of issue. The options issued have an exercise price of $4.35 per share, which was the last traded price of the common stock on the day issued. The options expire five years from date of issue. During the second quarter of 2014 the Company issued options to two of its directors pursuant to the Company's compensation policy for directors. Each director was issued options to purchase 46,875 shares of common stock. The options become exercisable in five equal annual installments starting on the date of issue. The options issued have an exercise price of $3.480 per share, which was the last traded price of the common stock on the day issued. The options expire five years from date of issue. The Company entered into an employment agreement, effective March 13, 2014 ("Employment Agreement"), with Mr. Sperzel to serve as the Company's Chief Executive Officer, which included issuing incentive and non-incentive stock options to purchase 250,000 shares of the Company's common stock. The options become exercisable in five equal annual installments starting on the first anniversary of the effective date of the Employment Agreement. The exercise price for these options was to be equal to the volume-weighted average trading price for the Company's common stock on March 13, 2014, which was $3.416 per share. The options expire seven years from date of issue. (d) Warrants As of December 31, 2016 and 2015, the Company had no warrants outstanding to purchase shares of common stock.

RIGHTS AGREEMENT

RIGHTS AGREEMENT	12 Months Ended
	Dec. 31, 2016
RIGHTS AGREEMENT [Abstract]
RIGHTS AGREEMENT	NOTE 10 — RIGHTS AGREEMENT: In March 2010, the Company entered into a Rights Agreement (the "Rights Agreement") between the Company and Action Stock Transfer Corp., as Rights Agent. The Rights Agreement expired at the end of November 2015. Pursuant to the Rights Agreement, the Company declared a dividend distribution of one preferred share purchase right (a "Right") for each outstanding share of Common Stock, $0.01 par value (the "Common Stock"), of the Company. The Board of Directors set the payment date for the distribution of the Rights as March 8, 2010, and the Rights were distributed to the Company's shareholders of record on that date. The description and terms of the Rights are set forth in the Rights Agreement. Rights Initially Not Exercisable. Separation and Distribution of Rights

EMPLOYEE STOCK OPTION PLAN

EMPLOYEE STOCK OPTION PLAN	12 Months Ended
	Dec. 31, 2016
EMPLOYEE STOCK OPTION PLAN [Abstract]
EMPLOYEE STOCK OPTION PLAN	NOTE 11 — EMPLOYEE STOCK OPTION PLAN: Effective June 3, 2008, the Company's stockholders voted to approve the 2008 Stock Incentive Plan ("SIP"), with 625,000 shares of Common Stock available to be issued. At the Annual Stockholder meeting on September 22, 2011 the Company's stockholders voted to approve an increase to the shares of Common Stock issuable under the SIP by 125,000 to 750,000. Under the terms of the SIP, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted. Awards can be stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee. As of December 31, 2016, there were 467,685 options exercised, 275,931 options outstanding and 6,384 options still available to be issued under the SIP. Effective June 19, 2014, the Company's stockholders voted to approve the 2014 Stock Incentive Plan ("SIP14"), with 800,000 shares of Common Stock available to be issued. Under the terms of the SIP14, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted. Awards can be stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee. As of December 31, 2016, there were 12,000 options exercised, 117,750 options outstanding and 670,250 options still available to be issued under the SIP14. The Company's results for the years ended December 31, 2016, 2015 and 2014 include stock-based compensation expense totaling $304,100, $334,400, and $447,100 respectively. Such amounts have been included in the Consolidated Statements of Operations within cost of goods sold ($-, $-, and $700 respectively), research and development ($89,200, $62,700, and $44,500 respectively) and selling, general and administrative expenses ($214,900, $271,700, and $401,900 respectively). In accordance with ASC 718 the Company has not recorded a deferred tax asset related to the net operating losses resulting from the exercise of disqualifying stock options in the accompanying financial statements. Stock option compensation expense in the years ended December 31, 2016, 2015 and 2014 represents the estimated fair value of options outstanding which is being amortized on a straight-line basis over the requisite vesting period of the entire award. The weighted average estimated fair value of stock options granted in the year ended December 31, 2016 was $2.75 per share. The Company did not grant any stock options during the year ended December 31, 2015 . The weighted average estimated fair value of stock options granted in the year ended December 31, 2014 was $3.52 per share. The fair value of options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of our stock and other contributing factors. The expected term is based on the Company's historical experience with similar type options. The weighted-average assumptions made in calculating the fair values of options are as follows: For the year ended December 31, 2016 December 31, 2015 December 31, 2014 Expected term (in years) 4.71 n/a 4.50-6.30 Expected volatility 45.78 % n/a 61.50-96.10% Expected dividend yield n/a n/a n/a Risk-free interest rate 0.92 % n/a .83-1.52% The Company granted 142,875 new options during the year ended December 31, 2016 to employees and directors. The following table provides stock options activity for the year ended December 31, 2016: Stock Options Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2013 656,398 2.57 1.65 years $ 801,888 Granted 379,750 3.52 Exercised 318,750 1.04 341,729 Forfeited/expired/cancelled 25,529 3.17 Outstanding at December 31, 2014 691,869 3.66 3.97 years $ 334,636 Exercisable at December 31, 2014 265,619 3.67 1.94 years $ 158,149 Outstanding at December 31, 2014 691,869 3.66 3.97 years $ 334,636 Granted - - Exercised 41,141 2.25 65,449 Forfeited/expired/cancelled 1,250 4.30 Outstanding at December 31, 2015 649,478 3.75 3.21 years $ 1,032,362 Exercisable at December 31, 2015 359,228 3.89 2.03 years $ 522,039 Outstanding at December 31, 2015 649,478 $ 3.75 3.21 years $ 1,032,362 Granted 142,875 $ 7.08 Exercised 191,804 $ 3.73 629,143 Forfeited/expired/cancelled - $ - Outstanding at December 31, 2016 600,549 $ 4.55 3.43 years $ 1,463,052 Exercisable at December 31, 2016 267,549 $ 4.14 2.66 years $ 731,997 The following table summarizes information about stock options outstanding at December 31, 2016: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Shares Average Remaining Contract Life (Year) Weighted Average Exercise Price Aggregate Intrinsic Value Shares Weighted Average Exercise Price Aggregate Intrinsic Value 1 to 2.79999 - - $ - $ - - $ - $ - 2.8 to 4.59999 419,719 3.30 3.60 1,342,788 220,219 3.71 681,333 4.6 to 6.39999 97,955 3.02 5.57 120,264 37,955 5.47 50,664 6.4 to 8.19999 36,000 4.78 7.15 - - - - 8.2 to 10 46,875 4.44 8.86 - 9,375 8.86 - Total 600,549 3.43 $ 4.55 $ 1,463,052 267,549 $ 4.14 $ 731,997 As of December 31, 2016, there was $386,000 of net unrecognized compensation cost related to stock options that are not vested, which is expected to be recognized over a weighted average period of approximately 2.32 years. The total fair value of shares vested during the year ended December 31, 2016, was $262,000.

GEOGRAPHIC INFORMATION AND ECON

GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY	12 Months Ended
	Dec. 31, 2016
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY [Abstract]
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY	NOTE 12 — GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY: FASB Guidance establishes standards for the way that business enterprises report information about operating segments in financial statements and requires that those enterprises report selected information. It also establishes standards for related disclosures about product and services, geographic areas, and major customers. The Company produces only one group of similar products known collectively as "rapid medical tests". Management believes that it operates in a single business segment. Net sales by geographic area are as follows: For the years ended December 31, 2016 December 31, 2015 December 31, 2014 Africa $ 2,363,944 $ 3,673,199 $ 2,097,353 Asia 227,564 172,250 96,061 Europe 1,131,193 1,164,476 191,947 North America 5,082,319 6,525,951 11,134,691 South America 4,875,087 10,350,812 12,429,717 $ 13,680,107 $ 21,886,688 $ 25,949,769 Sales to Africa decreased in 2016 primarily due to decreased sales in Uganda by approximately $1,122,400, and Nigeria by approximately $220,900. Sales in Asia increased slightly by $55,300. European sales decreased by $68,600. Sales decreased in 2016 to North America from decreased sales in the U.S by approximately $1,579,800 and partially offset by increased sales to Mexico of $123,200. Sales decreased in 2016 to South America were primarily from decreased sales in Brazil of approximately $5,340,250. Sales to Africa increased in 2015 primarily due to increased sales in Uganda by approximately $1,344,500, and Nigeria by approximately $287,500. Sales in Asia increased slightly by $76,200. European sales increased by $972,500. Sales decreased in 2015 to North America from decreased sales to Mexico of $3,913,400 and by decreased sales in the U.S by approximately $1,545,000. Sales decreased in 2015 to South America were primarily from decreased sales in Brazil of approximately $2,111,700.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2016
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 — COMMITMENTS AND CONTINGENCIES: Employment Contracts: The Company has contracts with three key employees. The contracts call for salaries presently aggregating $975,000 per year. One contract expires in May 2017, one expires in March 2019 and one contract expires in March 2017. The following table is a schedule of future minimum salary commitments: 2017 $ 516,200 2018 335,000 2019 55,800 Pension Plan: The Company has a 401(k) plan established for its employees. Effective January 1, 2011 the Company elected to match 40% of the first 5% (or 2% of salary) that an employee contributes to their 401(k) plan. Expenses related to this matching contribution aggregated $96,051, $90,915 and $82,750 for the years ended December 31, 2016, 2015, and 2014 respectively. Obligations Under Operating Leases: The Company leases industrial space used for office, R&D and manufacturing facilities, currently with a monthly rent of $28,688. The current lease expires on April 30, 2017. The lease provides for annual increases of 2.50% percent each year starting May 1, 2016. In February of 2014, the Company entered into a lease, effective March 1, 2014, for another facility located a short distance from its current facility currently with a monthly rent of $15,550. The space is used primarily for warehousing and provides for additional office space. The lease expires on April 30, 2018. The lease provides for annual increases of 3.00% percent each year starting March 1, 2016. The following is a schedule of future minimum rental commitments (assuming no increases): Years ending December 31, 2017 $ 306,018 2018 64,067 2019 - $ 370,085 Rent expense was $516,708, $511,900 and $476,000 for the years ended December 31, 2016, 2015, and 2014 respectively. Economic Dependency: The following table delineates sales the Company had to customers in excess of 10% of total sales for the periods indicated: For the years ended Accounts Receivable December 31, 2016 December 31, 2015 December 31, 2014 December 31, 2016 December 31, 2015 Sales % of Sales Sales % of Sales Sales % of Sales Customer 1 $ 4,801,577 35 % $ 10,132,512 46 % $ 12,253,526 47 % $ 828,848 $ 775,209 Customer 2 1,796,477 13 % 4,526,908 21 % 6,618,251 26 % - 700,656 The following table delineates purchases the Company had with vendors in excess of 10% of total purchases for the periods indicated: For the years ended Accounts Payable December 31, 2016 December 31, 2015 December 31, 2014 December 31, 2016 December 31, 2015 Purchases % of Purc. Purchases % of Purc. Purchases % of Purc. Vendor 1 $ 652,273 11 % $ * * $ * * $ 26,984 $ * Vendor 2 * * 794,536 11 % 1,331,647 14 % * 90,075 In the table above the asterisk (*) indicates that purchases from the vendor did not exceed 10% for the period indicated. The Company currently buys materials which are purchased under intellectual property rights agreements and are important components in its products. Management believes that other suppliers could provide similar materials on comparable terms. A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which would affect operating results adversely.

COLLABORATIVE RESEARCH AND DEVE

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	12 Months Ended
	Dec. 31, 2016
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS [Abstract]
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	NOTE 14 — COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS: In 2016, 2015, and 2014 the Company earned $3.7 million, $2.3 million, and $1.7 million, respectively, from research revenues and milestones. The Company is now involved in additional feasibility and development contracts related to its DPP® technology. The total expended on R&D, excluding regulatory, in 2016, 2015, and 2014, was approximately $6.9 million, $5.4 million, and $4.1 million, respectively. a. RVR DPP® technology transfer agreement: In February 2014, the Company entered into a technology transfer agreement with RVR Diagnostics for $1,500,000. The agreement was modified in September 2014 and September 2015. Per the agreement, as modified, the Company earned $-, $125,000 and $1,125,000 in milestone payments during 2016, 2015 and 2014. The Company has earned $1,250,000 from this grant from inception through December 31, 2016. See subsequent event note describing the Company's acquistion of RVR Diagnostics in January 2017. b. Dengue agreement: In October 2014, the Company entered into a development agreement with an international diagnostics company for $300,000. Revenue for this agreement is being recognized under a proportional performance method. For the years ended December 31, 2016, 2015 and 2014, the Company earned $-, $240,000 and $60,000, respectively from this grant. The Company has earned $300,000 from this grant from inception through December 31, 2016. c. Brain Injury agreement: In January 2015, the Company entered into a technology development agreement with Perseus Science Group LLC for $946,000 and a follow-on agreement in December 2016 for $350,000. Revenue for this agreement is being recognized under a proportional performance method. The Company earned $297,000 and $469,600 for the year ended December 31, 2016 and 2015, respectively from this agreement. The Company has earned $766,600 from this grant from inception through December 31, 2016. d. Malaria agreement: In January 2015, the Company was awarded a grant from The Bill & Melinda Gates Foundation for $307,000. Revenue for this agreement is being recognized under a proportional performance method. The Company earned $- and $307,000 for the year ended December 31, 2016 and 2015, respectively from this agreement. The Company has earned $307,000 from this grant from inception through December 31, 2016. In April 2016, the Company was awarded a grant from the Bill & Melinda Gates Foundation for $677,944. The Company earned $518,761 for the year ended December 31, 2016 from this agreement, which is the total amount earned from this grant from inception through December 31, 2016. e. Cancer agreement: In October 2014, the Company entered into a technology development agreement with an international diagnostics company for $320,000. Revenue for this agreement is being recognized under a proportional performance method. For the years ended December 31, 2016, 2015 and 2014, the Company earned $65,000, $205,000 and $-, respectively from this grant. The Company has earned $270,000 from this grant from inception through December 31, 2016. f. Fever panel agreement: In October 2015, the Company entered into an agreement with Paul G. Allen Ebola Program for $2,118,265 and a follow-on agreement in February 2016 for $550,000. Revenue for this agreement is being recognized under a proportional performance method. The Company earned $2,259,800 and $408,500 for the year ended December 31, 2016 and 2015, respectively from this agreement. The Company has earned $2,668,265 from this grant from inception through December 31, 2016. g. BARDA Zika agreement: In August 2016, the Company was awarded a grant for $5,933,742 from BARDA, which is part of the U.S. Department of Health And Human Resources. The Company earned $472,700 for the year ended December 31, 2016 from this agreement. The Company earned $472,700 from this grant from inception through December 31, 2016. h. USDA Bovid: In September 2016, the Company entered into an agreement with the USDA for $669,423 to develop a Bovid TB assay. Revenue for this agreement is being recognized under a proportional performance method. The Company earned $121,500 for the year ended December 31, 2016 from this agreement. Governmental Regulation: All of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration (FDA), United States Department of Agriculture, certain state and local agencies, and/or comparable regulatory bodies in other countries. Most aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing, and record keeping are subject to review. After marketing approval has been granted, Chembio must continue to comply with governmental regulations. Failure to comply with these regulations can result in significant penalties.

QUARTERLY FINANCIAL DATA (UNAUD

QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
	Dec. 31, 2016
QUARTERLY FINANCIAL DATA (UNAUDITED) [Abstract]
Quarterly Financial Information	NOTE 15 — QUARTERLY FINANCIAL DATA (UNAUDITED) The sum of the earnings per common share may not equal the corresponding annual amounts due to interim quarter rounding. For the Quarters Ended in Fiscal 2016 March 31 June 30 September 30 December 31 Total revenues $ 6,601,099 $ 3,266,405 $ 3,746,461 $ 4,254,876 Gross profit 3,165,548 1,580,305 1,952,097 1,753,386 Net loss (303,590 ) (8,347,482 ) (2,138,218 ) (2,557,757 ) Basic loss per share (0.03 ) (0.86 ) (0.19 ) (0.21 ) Diluted loss per share (0.03 ) (0.86 ) (0.19 ) (0.21 ) For the Quarters Ended in Fiscal 2015 March 31 June 30 September 30 December 31 Total revenues $ 6,231,137 $ 6,716,158 $ 6,887,374 $ 4,420,816 Gross profit 2,686,618 3,019,132 2,910,534 1,870,543 Net loss (646,817 ) (664,085 ) (437,157 ) (648,984 ) Basic loss per share (0.07 ) (0.07 ) (0.05 ) (0.07 ) Diluted loss per share (0.07 ) (0.07 ) (0.05 ) (0.07 )

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2016
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE 16 — SUBSEQUENT EVENTS: On January 9, 2017, the Company, completed the acquisition of RVR Diagnostics Sdn Bhd, a Malaysia corporation ("RVR"), pursuant to the previously reported Amended And Restated Stock Purchase Agreement, dated as of December 7, 2016 (the "Stock Purchase Agreement"), by and among the Company, RVR, Avijit Roy and Magentiren Vajuram (Messrs. Roy and Vajuram, the "Sellers"). Pursuant to the Stock Purchase Agreement, the Company acquired all of the issued and outstanding common stock and other equity interests of RVR from the Sellers for (i) a cash payment of $1,400,000 and (ii) 269,236 shares of the Company's common stock, of which 7,277 shares are being held back to satisfy certain potential claims under the Stock Purchase Agreement and will become issuable to the Sellers, if at all, on the one-year anniversary of the closing. In addition, the Stock Purchase Agreement provides that the Sellers may become entitled to receive certain milestone payments based on the achievement of performance goals related to sales by RVR during the 12 months ending December 31, 2017. Based on the actual sales achieved by RVR, the Sellers will be entitled to receive (i) a cash milestone payment equal to $100,000 multiplied by the Milestone Proration Amount, for a maximum cash milestone payment of $100,000, and (ii) a stock milestone payment equal to 21,830 shares of the Company's common stock multiplied by the Milestone Proration Amount, with a maximum stock milestone payment of 21,830 shares of the Company's common stock. In connection with the closing of the transaction under the Stock Purchase Agreement, each of the Sellers entered into an employment agreement with RVR, pursuant to which, among other things, each of the Sellers agreed to serve as an employee of RVR for the one-year period following the closing in exchange for a monthly base salary of $10,000. In addition, at the closing, John J. Sperzel III, the Company's President, Chief Executive Officer and a member of the Company's board of directors, Richard J. Larkin, the Company's Chief Financial Officer and Executive Vice President, and Katherine L. Davis, the Company's Chairman of the Board and a member of the Company's board of directors, were appointed as the directors of RVR, with each of the Sellers continuing as the other two directors of RVR.

SIGNIFICANT ACCOUNTING POLICI23

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2016
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Principles of Consolidation	(a) Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	(b) Use of Estimates: The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make assumptions and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods covered thereby. Actual results could differ from these estimates. Judgments and estimates of uncertainties are required in applying the Company's accounting policies in certain areas. The following are some of the areas requiring significant judgments and estimates: determinations of the useful lives of assets, estimates of allowances for doubtful accounts, inventory reserves, stock-based compensation and deferred tax assets.
Fair Value of Financial Instruments	(c) Fair Value of Financial Instruments: The carrying value for cash and cash equivalents, accounts receivable and accounts payable, approximate fair value because of the immediate or short-term maturity of these financial instruments.
Statements of Cash Flows	(d) Statements of Cash Flows: For purposes of the statements of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Concentrations of Credit Risk	(e) Concentrations of Credit Risk: Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments and trade receivables. The Company places its temporary cash instruments with well-known financial institutions and, at times, may maintain balances in excess of the FDIC insurance limit. The Company monitors the credit ratings of the financial institutions to mitigate this risk. Concentration of credit risk with respect to trade receivables is principally mitigated by the Company's ability to obtain letters of credit from certain foreign customers, and its diverse customer base both in number of customers and geographic locations.
Inventories	(f) Inventories: Inventories, consisting of material, labor and manufacturing overhead, are stated at the lower of cost or market. Cost is determined on the first-in, first-out method.
Fixed Assets	(g) Fixed Assets: Fixed assets are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which range from three to seven years. Leasehold improvements are amortized over the useful life of the asset or the lease term, whichever is shorter. Deposits paid for fixed assets are capitalized and not depreciated until the related asset is placed in service.
License Agreement	(h) License Agreements: In February 2008, the Company entered into a sublicense agreement for which it had initially recorded an asset of $1,000,000. This asset is being expensed over an estimated economic life of ten years, based on the expected lifespan of our then current HIV products. The current portion of this asset is $100,000 as of December 31, 2016 and 2015 and is reported in prepaid expenses and other current assets. The long-term portion as of December 31, 2016 and 2015 is $- and $100,000, respectively and is reflected in other assets on the consolidated balance sheet. In January 2015, the Company entered into a sublicense agreement for which it had initially recorded an asset of $400,000. This asset is being expensed over the life of the patent of 22 months. The current portion of this asset is $- and $181,818 as of December 31, 2016 and 2015, respectively and is reported in prepaid expenses. The long-term portion as of December 31, 2016 and 2015 is $- and $-, respectively and is reflected in other assets on the consolidated balance sheet. In August 2015, the Company entered into a sublicense agreement for which it had initially recorded an asset of $100,000. This asset is being validated and will be expensed over the estimated economic life of the product(s) which will utilize this sublicense. The current portion of this asset is $100,000 as of December 31, 2016 and 2015 and is reported in prepaid expenses and other current assets. The long-term portion of this asset is $- as of December 31, 2016 and 2015. Amortization expenses for the licenses above for the years ended December 31, 2016, 2015 and 2014 were $357,000, $479,000 and $122,000.
Impairment of Long-Lived Assets and Intangible Assets	(i) Impairment of Long-Lived Assets and Intangible Assets Long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. We believe that the carrying values of our long-lived tangible and intangible assets were realizable at December 31, 2016 and 2015, respectively.
Revenue Recognition	(j) Revenue Recognition: The Company recognizes revenue for product sales in accordance with ASC 605, revenue is recognized when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is fixed and determinable, and collectability is reasonably assured. Revenue typically is recognized at time of shipment. Sales are recorded net of discounts, rebates and returns. For certain contracts, the Company recognizes revenue from non-milestone contracts and grant revenues when earned. Grants are invoiced after expenses are incurred. Revenues from projects or grants funded in advance are deferred until earned. The Company follows Financial Accounting Standards Board ("FASB") Accounting Standards for the recognition of revenue under the milestone method. The Company applies the milestone method of revenue recognition for certain collaborative research projects defining milestones at the inception of the agreement.
Research and Development	(k) Research and Development: Research and development (R&D) costs are expensed as incurred.
Stock-Based Compensation	(l) Stock-Based Compensation: Stock-based compensation expense is calculated using the Black-Scholes valuation model based on awards ultimately expected to vest, reduced for forfeitures, and expensed on a straight-line basis over the requisite service period of the grant.
Income Taxes	(m) I ncome Taxes: The Company accounts for income taxes under an asset and liability approach which recognizes deferred tax assets and liabilities based on the difference between the financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company follows a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The guidance relates to, among other things, classification, accounting for interest and penalties associated with tax positions, and disclosure requirements. Any interest and penalties accrued related to uncertain tax positions will be recorded in tax expense. The Company assesses the realizability of its net deferred tax assets on an annual basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, the Company would reduce the net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of net operating loss carryforwards.
Loss Per Share	(n) Loss Per Share The following weighted average shares were used for the computation of basic and diluted earnings per share: For the years ended December 31, 2016 December 31, 2015 December 31, 2014 Basic 10,622,331 9,626,028 9,530,320 Diluted 10,622,331 9,626,028 9,530,320 Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share for the year ended December 31, 2016, 2015 and 2014 reflects the potential dilution from the exercise or conversion of other securities into common stock, if dilutive. The following securities, presented on a common share equivalent basis, have been used in the diluted per share computations: For the years ended December 31, 2016 December 31, 2015 December 31, 2014 1999, 2008 and 2014 Plan Stock Options - - - There were 600,549, 658,631 and 798,475 options and warrants outstanding as of December 31, 2016, 2015 and 2014, respectively, which were not included in the calculation of diluted income per share for the years ended because their effect would have been anti-dilutive.
Recent Accounting Pronouncements Affecting the Company	(o) Recent Accounting Pronouncements Affecting the Company: In May 2014, the FASB issued Accounting Standards Update No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09"), which supersedes nearly all existing revenue recognition guidance under accounting principles generally accepted in the United States ("U.S. GAAP"). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018. The Company has conducted a preliminary analysis of its sales contracts which are based on the shipment of goods to the customer, and currently this new accounting standard will not have a material impact on its consolidated financial statement for our sales contracts. The Company has conducted a preliminary analysis of its current R&D contracts which are currently based on "as expenses are incurred" basis, and currently this new accounting standard will not have a material impact on its consolidated financial statement for our current R&D contracts. In November 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-17, Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and will require an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the current guidance, entities are required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. This guidance will be effective for Chembio beginning in 2018, with early adoption permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update ("ASU") 2016-02, which amends the ASC and creates Topic 842, Leases. Topic 842 will require lessees to recognize lease assets and lease liabilities for those leases classified as operating leases under previous US GAAP on the balance sheet. This guidance is effective for annual periods beginning after December 15, 2018 and early adoption is permitted. We are in the initial stages of evaluating the effect of the standard on our financial statements and will continue to evaluate. While not yet in a position to assess the full impact of the application of the new standard, the Company expects that the impact of recording the lease liabilities and the corresponding right-to-use assets will have a significant impact on its total assets and liabilities with a minimal impact on equity. In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which will change certain aspects of accounting for share-based payments to employees. ASU 2016-09 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2016. The Company is currently in the initial stages of evaluating the impact of the provisions of ASU 2016-09. We are still evaluating this standard and currently the Company does not believe this new accounting standard will have a material impact on its consolidated financial statement.

SIGNIFICANT ACCOUNTING POLICI24

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2016
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Schedule of weighted average shares used for computation of basic and diluted earnings per share	The following weighted average shares were used for the computation of basic and diluted earnings per share: For the years ended December 31, 2016 December 31, 2015 December 31, 2014 Basic 10,622,331 9,626,028 9,530,320 Diluted 10,622,331 9,626,028 9,530,320
Schedule of common share equivalent basis, used in diluted per share computations	The following securities, presented on a common share equivalent basis, have been used in the diluted per share computations: For the years ended December 31, 2016 December 31, 2015 December 31, 2014 1999, 2008 and 2014 Plan Stock Options - - -

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2016
INVENTORIES [Abstract]
Schedule of inventories	Inventories consist of the following at: December 31, 2016 December 31, 2015 Raw materials $ 1,824,248 $ 2,248,371 Work in process 535,320 370,340 Finished goods 975,620 959,314 $ 3,335,188 $ 3,578,025

FIXED ASSETS (Tables)

FIXED ASSETS (Tables)	12 Months Ended
	Dec. 31, 2016
FIXED ASSETS [Abstract]
Schedule of fixed assets	Fixed assets consist of the following at: December 31, 2016 December 31, 2015 Machinery and equipment $ 3,962,051 $ 3,862,698 Furniture and fixtures 437,962 436,588 Computer and telephone equipment 343,167 326,170 Leasehold improvements 2,012,945 2,012,945 6,756,125 6,638,401 Less accumulated depreciation and amortization (5,046,804 ) (4,264,093 ) $ 1,709,321 $ 2,374,308

ACCOUNTS PAYABLE AND ACCRUED 27

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2016
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract]
Schedule of accounts payable and accrued liabilities	Accounts payable and accrued liabilities consist of the following at: December 31, 2016 December 31, 2015 Accounts payable – suppliers $ 1,437,290 $ 1,260,520 Accrued commissions 221,982 129,192 Accrued royalties / license fees 352,660 732,301 Accrued payroll 167,575 146,962 Accrued vacation 289,587 244,810 Accrued bonuses 282,500 177,700 Accrued expenses – other 261,539 109,947 TOTAL $ 3,013,133 $ 2,801,432

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
INCOME TAXES [Abstract]
Schedule of provision (benefit) for income taxes	The (benefit from) provision for income taxes for the years ended December 31, 2016 and 2015, is comprised of the following: 2016 2015 2014 Current Federal $ - $ - $ (16,119 ) State - 10,726 6,576 Total current (benefit) provision - 10,726 (9,543 ) Deferred Federal 5,778,185 (1,171,865 ) (449,452 ) State 22,633 896 46,077 Total deferred (benefit) provision 5,800,818 (1,170,969 ) (403,375 ) Total (benefit) provision $ 5,800,818 $ (1,160,243 ) (412,918 )
Schedule of deferred tax assets	2016 2015 Current assets Inventory reserves $ 253,380 $ 242,532 Accrued expenses 53,140 91,143 Current deferred tax assets 306,520 333,675 Less valuation allowances (306,520 ) - Net current deferred asset $ - $ 333,675 Noncurrent assets Net operating loss carry-forwards $ 7,487,937 $ 5,365,401 Research and development credit 1,461,351 1,518,414 Other credits 97,339 97,339 Depreciation 31,285 (206,150 ) Other 292,556 210,553 Noncurrent deferred tax assets 9,370,468 6,985,557 Less valuation allowances (9,370,468 ) (1,518,414 ) Net noncurrent deferred tax assets $ - $ 5,467,143
Schedule of reconciliation of the Federal statutory rate to the effective rate applicable to income (loss) before income taxes	A reconciliation of the Federal statutory rate to the effective rate applicable to income (loss) before income taxes is as follows: Year Ending December 31, 2016 2015 2014 Federal income tax at statutory rates (34.00)% (34.00)% (34.00)% State income taxes, net of federal benefit .21% 0.23% 0.28% Nondeductible expenses .57% 1.38% 4.54% Change in valuation allowance 114.81% 9.46% 9.47% Tax credits .00% (9.46)% (9.47)% Change in tax rates .00% 0.00% 1.96% Other .04% 0.34% 0.58% Income tax (benefit) 81.63% (32.05)% (26.64)%

EMPLOYEE STOCK OPTION PLAN (Tab

EMPLOYEE STOCK OPTION PLAN (Tables)	12 Months Ended
	Dec. 31, 2016
EMPLOYEE STOCK OPTION PLAN [Abstract]
Assumptions made in calculating the fair values of options	The weighted-average assumptions made in calculating the fair values of options are as follows: For the year ended December 31, 2016 December 31, 2015 December 31, 2014 Expected term (in years) 4.71 n/a 4.50-6.30 Expected volatility 45.78 % n/a 61.50-96.10% Expected dividend yield n/a n/a n/a Risk-free interest rate 0.92 % n/a .83-1.52%
Stock options activity	The following table provides stock options activity for the year ended December 31, 2016: Stock Options Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2013 656,398 2.57 1.65 years $ 801,888 Granted 379,750 3.52 Exercised 318,750 1.04 341,729 Forfeited/expired/cancelled 25,529 3.17 Outstanding at December 31, 2014 691,869 3.66 3.97 years $ 334,636 Exercisable at December 31, 2014 265,619 3.67 1.94 years $ 158,149 Outstanding at December 31, 2014 691,869 3.66 3.97 years $ 334,636 Granted - - Exercised 41,141 2.25 65,449 Forfeited/expired/cancelled 1,250 4.30 Outstanding at December 31, 2015 649,478 3.75 3.21 years $ 1,032,362 Exercisable at December 31, 2015 359,228 3.89 2.03 years $ 522,039 Outstanding at December 31, 2015 649,478 $ 3.75 3.21 years $ 1,032,362 Granted 142,875 $ 7.08 Exercised 191,804 $ 3.73 629,143 Forfeited/expired/cancelled - $ - Outstanding at December 31, 2016 600,549 $ 4.55 3.43 years $ 1,463,052 Exercisable at December 31, 2016 267,549 $ 4.14 2.66 years $ 731,997
Summary of stock options outstanding	The following table summarizes information about stock options outstanding at December 31, 2016: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Shares Average Remaining Contract Life (Year) Weighted Average Exercise Price Aggregate Intrinsic Value Shares Weighted Average Exercise Price Aggregate Intrinsic Value 1 to 2.79999 - - $ - $ - - $ - $ - 2.8 to 4.59999 419,719 3.30 3.60 1,342,788 220,219 3.71 681,333 4.6 to 6.39999 97,955 3.02 5.57 120,264 37,955 5.47 50,664 6.4 to 8.19999 36,000 4.78 7.15 - - - - 8.2 to 10 46,875 4.44 8.86 - 9,375 8.86 - Total 600,549 3.43 $ 4.55 $ 1,463,052 267,549 $ 4.14 $ 731,997

GEOGRAPHIC INFORMATION AND EC30

GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Tables)	12 Months Ended
	Dec. 31, 2016
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY [Abstract]
Net sales by geographic area	The Company produces only one group of similar products known collectively as "rapid medical tests". Management believes that it operates in a single business segment. Net sales by geographic area are as follows: For the years ended December 31, 2016 December 31, 2015 December 31, 2014 Africa $ 2,363,944 $ 3,673,199 $ 2,097,353 Asia 227,564 172,250 96,061 Europe 1,131,193 1,164,476 191,947 North America 5,082,319 6,525,951 11,134,691 South America 4,875,087 10,350,812 12,429,717 $ 13,680,107 $ 21,886,688 $ 25,949,769

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2016
COMMITMENTS AND CONTINGENCIES [Abstract]
Schedule of future minimum salary commitment	The Company has contracts with three key employees. The contracts call for salaries presently aggregating $975,000 per year. One contract expires in May 2017, one expires in March 2019 and one contract expires in March 2017. The following table is a schedule of future minimum salary commitments: 2017 $ 516,200 2018 335,000 2019 55,800
Schedule of future minimum rental commitments	The following is a schedule of future minimum rental commitments (assuming no increases): Years ending December 31, 2017 $ 306,018 2018 64,067 2019 - $ 370,085
Customer and purchase concentration risks	The following table delineates sales the Company had to customers in excess of 10% of total sales for the periods indicated: For the years ended Accounts Receivable December 31, 2016 December 31, 2015 December 31, 2014 December 31, 2016 December 31, 2015 Sales % of Sales Sales % of Sales Sales % of Sales Customer 1 $ 4,801,577 35 % $ 10,132,512 46 % $ 12,253,526 47 % $ 828,848 $ 775,209 Customer 2 1,796,477 13 % 4,526,908 21 % 6,618,251 26 % - 700,656 The following table delineates purchases the Company had with vendors in excess of 10% of total purchases for the periods indicated: For the years ended Accounts Payable December 31, 2016 December 31, 2015 December 31, 2014 December 31, 2016 December 31, 2015 Purchases % of Purc. Purchases % of Purc. Purchases % of Purc. Vendor 1 $ 652,273 11 % $ * * $ * * $ 26,984 $ * Vendor 2 * * 794,536 11 % 1,331,647 14 % * 90,075 In the table above the asterisk (*) indicates that purchases from the vendor did not exceed 10% for the period indicated.

QUARTERLY FINANCIAL DATA (UNA32

QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	12 Months Ended
	Dec. 31, 2016
QUARTERLY FINANCIAL DATA (UNAUDITED) [Abstract]
Quarterly Financial Information	The sum of the earnings per common share may not equal the corresponding annual amounts due to interim quarter rounding. For the Quarters Ended in Fiscal 2016 March 31 June 30 September 30 December 31 Total revenues $ 6,601,099 $ 3,266,405 $ 3,746,461 $ 4,254,876 Gross profit 3,165,548 1,580,305 1,952,097 1,753,386 Net loss (303,590 ) (8,347,482 ) (2,138,218 ) (2,557,757 ) Basic loss per share (0.03 ) (0.86 ) (0.19 ) (0.21 ) Diluted loss per share (0.03 ) (0.86 ) (0.19 ) (0.21 ) For the Quarters Ended in Fiscal 2015 March 31 June 30 September 30 December 31 Total revenues $ 6,231,137 $ 6,716,158 $ 6,887,374 $ 4,420,816 Gross profit 2,686,618 3,019,132 2,910,534 1,870,543 Net loss (646,817 ) (664,085 ) (437,157 ) (648,984 ) Basic loss per share (0.07 ) (0.07 ) (0.05 ) (0.07 ) Diluted loss per share (0.07 ) (0.07 ) (0.05 ) (0.07 )

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details)	12 Months Ended
	Dec. 31, 2016
Lateral Flow Rapid HIV Tests [Member]
Product Information [Line Items]
Concentration risk, percentage	58.00%
Patented DPP Platform [Member]
Product Information [Line Items]
Concentration risk, percentage	40.00%
Other Rapid Tests [Member]
Product Information [Line Items]
Concentration risk, percentage	2.00%

SIGNIFICANT ACCOUNTING POLICI34

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Aug. 31, 2015	Jan. 31, 2015	Feb. 28, 2008
Finite-Lived Intangible Assets [Line Items]
Current portion of license agreement	$ 100,000
Long term portion of license agreement	$ 0	$ 100,000
Summary of weighted average shares used for computation of basic and diluted earnings per share [Abstract]
Basic (in shares)	10,622,331	9,626,028	9,530,320
Diluted (in shares)	10,622,331	9,626,028	9,530,320
Summary of common share equivalent basis, used in diluted per share computations [Abstract]
1999, 2008 and 2014 Plan Stock Options (in shares)	0	0	0
Options and warrants excluded from computation of earnings per share (in shares)	600,549	658,631	798,475
Minimum [Member]
Fixed Assets [Abstract]
Estimated useful lives of fixed assets	3 years
Maximum [Member]
Fixed Assets [Abstract]
Estimated useful lives of fixed assets	7 years
License-BioRad [Member]
License Agreement [Abstract]
License agreement						$ 1,000,000
Estimated economic life	10 years
License-Kitgen [Member]
Finite-Lived Intangible Assets [Line Items]
Current portion of license agreement	$ 100,000
Long term portion of license agreement	0
License Agreement [Abstract]
License agreement				$ 100,000
License-SDS [Member]
Finite-Lived Intangible Assets [Line Items]
Current portion of license agreement	0	$ 181,818
Long term portion of license agreement	$ 0	$ 0
License Agreement [Abstract]
License agreement					$ 400,000
Estimated economic life	22 months

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials	$ 1,824,248	$ 2,248,371
Work in process	535,320	370,340
Finished goods	975,620	959,314
Inventories	$ 3,335,188	$ 3,578,025

FIXED ASSETS (Details)

FIXED ASSETS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Summary of fixed assets [Abstract]
Fixed assets, gross	$ 6,756,125	$ 6,638,401
Less accumulated depreciation	(5,046,804)	(4,264,093)
Fixed assets, net	1,709,321	2,374,308
Depreciation expense	782,711	893,305	$ 616,943
Amortization	356,517	479,258	$ 122,354
Deposits on various pieces of equipment	31,900	30,918
Machinery and Equipment [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	3,962,051	3,862,698
Furniture and Fixtures [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	437,962	436,588
Computer and Telephone Equipment [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	343,167	326,170
Leasehold Improvements [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	2,012,945	$ 2,012,945
Capital Leases [Member]
Summary of fixed assets [Abstract]
Fixed assets, net	0
Equipment Undergoing Validation [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	$ 199,921

ACCOUNTS PAYABLE AND ACCRUED 37

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Summary of accounts payable and accrued liabilities [Abstract]
Accounts payable - suppliers	$ 1,437,290	$ 1,260,520
Accrued commissions	221,982	129,192
Accrued royalties / license fees	352,660	732,301
Accrued payroll	167,575	146,962
Accrued vacation	289,587	244,810
Accrued bonuses	282,500	177,700
Accrued expenses - other	261,539	109,947
TOTAL	$ 3,013,133	$ 2,801,432

DEFERRED RESEARCH AND DEVELOP38

DEFERRED RESEARCH AND DEVELOPMENT REVENUE (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
DEFERRED RESEARCH AND DEVELOPMENT REVENUE [Abstract]
Deferred revenue	$ 392,517	$ 353,406

TERM NOTE, REVOLVING DEMAND N39

TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Line of credit, drawn down amount	$ 0	$ 700,000	$ 0
Demand Note [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 2,000,000
Clean-up period	30 days

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended				36 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2003	Dec. 31, 2006
Current [Abstract]
Federal	$ 0	$ 0	$ (16,119)
State	0	10,726	6,576
Total current (benefit) provision	0	10,726	(9,543)
Deferred [Abstract]
Federal	5,778,185	(1,171,865)	(449,452)
State	22,633	896	46,077
Total deferred (benefit) provision	5,800,818	(1,170,969)	(403,375)
Total (benefit) provision	5,800,818	(1,160,243)	(412,918)
Operating Loss Carryforwards [Line Items]
Net operating losses	21,960,362			$ 5,832,516	$ 8,586,861
Annual limitation				$ 150,608	$ 1,111,831
Period of built-in gains				5 years	5 years
Built-in-gains of net operating losses				$ 488,207	$ 1,756,842
Current assets [Abstract]
Inventory reserves	253,380	242,532	311,931
Accrued expenses	53,140	91,143	286,616
Current deferred tax assets	306,520	333,675	598,547
Less valuation allowances	(306,520)	0	0
Net current deferred asset	0	333,675	598,547
Noncurrent assets [Abstract]
Net operating loss carry-forwards	7,487,937	5,365,401	3,986,618
Research and development credit	1,461,351	1,518,414	1,175,725
Other credits	97,339	97,339	107,967
Other	292,556	210,553	149,923
Gross noncurrent deferred tax assets	9,339,183	7,191,707	5,420,233
Depreciation	31,285	(206,150)	(213,206)
Noncurrent deferred tax assets	9,370,468	6,985,557	5,207,027
Less valuation allowances	(9,370,468)	(1,518,414)	(1,175,725)
Net noncurrent deferred tax assets	$ 0	$ 5,467,143	$ 4,031,302
Summary of reconciliation of the Federal statutory rate to the effective rate applicable to income (loss) before income taxes [Abstract]
Federal income tax at statutory rates	(34.00%)	(34.00%)	(34.00%)
State income taxes, net of federal benefit	0.21%	0.23%	0.28%
Nondeductible expenses	0.57%	1.38%	4.54%
Change in valuation allowance	114.81%	9.46%	9.47%
Tax credits	0.00%	(9.46%)	(9.47%)
Change in tax rates	0.00%	0.00%	1.96%
Other	0.04%	0.34%	0.58%
Income tax (benefit)	81.63%	(32.05%)	(26.64%)
Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration dates	Dec. 31, 2020			Dec. 31, 2018	Dec. 31, 2018
Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration dates	Dec. 31, 2036			Dec. 31, 2024	Dec. 31, 2028
Research and Development Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward	$ 1,461,351
Research and Development Tax Credit Carryforward [Member] | Minimum [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, expiration date	Dec. 31, 2025
Research and Development Tax Credit Carryforward [Member] | Maximum [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, expiration date	Dec. 31, 2036
Federal [Member] | Minimum [Member]
Income Tax Contingency [Line Items]
Open tax year	2,013
Federal [Member] | Maximum [Member]
Income Tax Contingency [Line Items]
Open tax year	2,015

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details)	Aug. 03, 2016USD ($)	Mar. 05, 2016shares$ / shares	Mar. 13, 2014shares$ / shares	Aug. 31, 2016$ / sharesshares	Jun. 30, 2016sharesDirector$ / shares	Mar. 31, 2016shares$ / shares	Dec. 31, 2014shares$ / shares	Jun. 30, 2014shares$ / shares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares
Common Stock [Abstract]
Shares sold in underwritten public offering (in shares)				2,300,000
Price per share of common stock sold in the offering (in dollars per share) | $ / shares				$ 6
Proceeds from sale of offering | $	$ 12,493,398								$ 12,493,398	$ 0	$ 0
Number of stock options exercised under the plan (in shares)									191,804	41,141	318,750
Exercised (in shares)									98,599	17,109	286,356
Exercise prices of stock option, minimum (in dollars per share) | $ / shares									$ 2.80	$ 2.16	$ 1.04
Exercise prices of stock option, maximum (in dollars per share) | $ / shares									$ 5.56	$ 3.60	1.04
Exercise prices of stock option (in dollars per share) | $ / shares											$ 1.04
Preferred Stock [Abstract]
Preferred stock - shares authorized (in shares)									10,000,000	10,000,000
Preferred stock - shares outstanding (in shares)									0	0
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Reduced attributable expense | $									$ 304,154	$ 334,386	$ 447,100
Warrants [Abstract]
Warrants outstanding (in shares)									0
Newly Hired Presidents [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)						36,000
Exercise price of stock option (in dollars per share) | $ / shares						$ 7.15
Expiration period of stock option						5 years	5 years
Number of equal annual installments with in which options are exercisable						3	3
BOD [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)					46,875			46,875
Exercise price of stock option (in dollars per share) | $ / shares					$ 8.860			$ 3.480
Expiration period of stock option					5 years			5 years
Number of equal annual installments with in which options are exercisable					5			5
Number of director, stock option issued | Director					1
New Vice Presidents [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)							36,000
Exercise price of stock option (in dollars per share) | $ / shares							$ 4.35
EVP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)		60,000
Exercise price of stock option (in dollars per share) | $ / shares		$ 5.64
Expiration period of stock option		5 years
Minimum period after termination of employment to exercise stock options by employees		30 years
Options expected to vest in each anniversary (in shares)									20,000
Options vested (in shares)									20,000
Number of equal annual installments with in which options are exercisable		3
CEO [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)			250,000
Exercise price of stock option (in dollars per share) | $ / shares			$ 3.416
Expiration period of stock option			7 years
Number of equal annual installments with in which options are exercisable			5

RIGHTS AGREEMENT (Details)

RIGHTS AGREEMENT (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
RIGHTS AGREEMENT [Abstract]
Preferred stock dividend declared for each common stock (in shares)	1
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Minimum combined ownership of outstanding shares of common stock by acquiring person	20.00%

EMPLOYEE STOCK OPTION PLAN (Det

EMPLOYEE STOCK OPTION PLAN (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options exercised under the plan (in shares)	191,804	41,141	318,750
Stock options, number of shares [Roll forward]
Exercised (in shares)	191,804	41,141	318,750
Stock options, weighted average exercise price per share [Roll Forward]
Exercised (in dollars per share)			$ 1.04
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period	$ 1,463,052
Exercisable, aggregate intrinsic value, end of period	731,997
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 304,100	$ 334,400	$ 447,100
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding under the plan (in shares)	649,478	691,869	691,869	656,398	600,549	649,478	691,869
Number of stock options exercised under the plan (in shares)	191,804	41,141	318,750
Weighted average estimated grant-date fair value of stock options granted (in dollars per share)	$ 2.75		$ 3.52
Assumptions made in calculating fair values of options [Abstract]
Expected volatility minimum	45.78%		61.50%
Expected volatility maximum			96.10%
Risk-free interest rate minimum	0.92%		0.83%
Risk-free interest rate minimum			1.52%
Stock options, number of shares [Roll forward]
Outstanding, beginning of period (in shares)	649,478	691,869	656,398
Granted (in shares)	142,875	0	379,750
Exercised (in shares)	191,804	41,141	318,750
Forfeited/expired/cancelled (in shares)	0	1,250	25,529
Outstanding, end of period (in shares)	600,549	649,478	691,869	656,398
Exercisable, end of period (in shares)	267,549	359,228	265,619
Stock options, weighted average exercise price per share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 3.75	$ 3.66	$ 2.57
Granted (in dollars per share)	7.08	0	3.52
Exercised (in dollars per share)	3.73	2.25	1.04
Forfeited/expired/cancelled (in dollars per share)	0	4.30	3.17
Outstanding, end of period (in dollars per share)	4.55	3.75	3.66	$ 2.57
Exercisable, end of period (in dollars per share)	$ 4.14	$ 3.89	$ 3.67
Stock options, additional disclosure [Abstract]
Outstanding, weighted average remaining contractual term	3 years 5 months 5 days	3 years 2 months 16 days	3 years 11 months 19 days	1 year 7 months 24 days
Exercisable, weighted average remaining contractual term	2 years 7 months 28 days	2 years 11 days	1 year 11 months 19 days
Outstanding, aggregate intrinsic value, beginning of period	$ 1,032,362	$ 334,636	$ 801,888
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	629,143	65,449	341,729
Outstanding, aggregate intrinsic value, end of period	1,463,052	1,032,362	334,636	$ 801,888
Exercisable, aggregate intrinsic value, end of period	$ 731,997	$ 522,039	$ 158,149
Net unrecognized compensation cost					$ 386,000	$ 297,000	$ 631,000
Weighted average period for recognition of net unrecognized compensation cost	2 years 3 months 25 days	2 years 18 days	2 years 4 months 17 days
Total fair value of stock options vested during period	$ 262,000	$ 357,000	$ 283,000
Stock Options [Member] | Minimum [Member]
Assumptions made in calculating fair values of options [Abstract]
Expected term	4 years 8 months 16 days		4 years 6 months
Stock Options [Member] | Maximum [Member]
Assumptions made in calculating fair values of options [Abstract]
Expected term			6 years 3 months 18 days
2008 Stock Incentive Plan [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)					750,000			625,000
Increase in number of shares authorized (in shares)	125,000
Number of stock options outstanding under the plan (in shares)	275,931				275,931
Number of stock options exercised under the plan (in shares)	467,685
Options still available to be issued (in shares)					6,384
Stock options, number of shares [Roll forward]
Exercised (in shares)	467,685
Outstanding, end of period (in shares)	275,931
2014 Stock Incentive Plan [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)							800,000
Number of stock options outstanding under the plan (in shares)	117,750				117,750
Number of stock options exercised under the plan (in shares)	12,000
Options still available to be issued (in shares)					670,250
Stock options, number of shares [Roll forward]
Exercised (in shares)	12,000
Outstanding, end of period (in shares)	117,750
Cost of Goods Sold [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 0	0	$ 700
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	89,200	62,700	44,500
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 214,900	$ 271,700	$ 401,900

EMPLOYEE STOCK OPTION PLAN, Par

EMPLOYEE STOCK OPTION PLAN, Part 2 (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 2.80	$ 2.16	$ 1.04
Range of exercise prices, maximum (in dollars per share)	$ 5.56	$ 3.60	$ 1.04
Stock Options Outstanding [Abstract]
Shares (in shares)	600,549
Average remaining contract life	3 years 5 months 5 days
Weighted average exercise price (in dollars per share)	$ 4.55
Aggregate intrinsic value	$ 1,463,052
Stock Options Exercisable [Abstract]
Shares (in shares)	267,549
Weighted average exercise price (in dollars per share)	$ 4.14
Aggregate intrinsic value	$ 731,997
1 to 2.79999 [Member]
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 1
Range of exercise prices, maximum (in dollars per share)	$ 2.79999
Stock Options Outstanding [Abstract]
Shares (in shares)	0
Average remaining contract life	0 years
Weighted average exercise price (in dollars per share)	$ 0
Aggregate intrinsic value	$ 0
Stock Options Exercisable [Abstract]
Shares (in shares)	0
Weighted average exercise price (in dollars per share)	$ 0
Aggregate intrinsic value	$ 0
2.8 to 4.59999 [Member]
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 2.8
Range of exercise prices, maximum (in dollars per share)	$ 4.59999
Stock Options Outstanding [Abstract]
Shares (in shares)	419,719
Average remaining contract life	3 years 3 months 18 days
Weighted average exercise price (in dollars per share)	$ 3.60
Aggregate intrinsic value	$ 1,342,788
Stock Options Exercisable [Abstract]
Shares (in shares)	220,219
Weighted average exercise price (in dollars per share)	$ 3.71
Aggregate intrinsic value	$ 681,333
4.6 to 6.39999 [Member]
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 4.6
Range of exercise prices, maximum (in dollars per share)	$ 6.39999
Stock Options Outstanding [Abstract]
Shares (in shares)	97,955
Average remaining contract life	3 years 7 days
Weighted average exercise price (in dollars per share)	$ 5.57
Aggregate intrinsic value	$ 120,264
Stock Options Exercisable [Abstract]
Shares (in shares)	37,955
Weighted average exercise price (in dollars per share)	$ 5.47
Aggregate intrinsic value	$ 50,664
6.4 to 8.19999 [Member]
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 6.4
Range of exercise prices, maximum (in dollars per share)	$ 8.19999
Stock Options Outstanding [Abstract]
Shares (in shares)	36,000
Average remaining contract life	4 years 9 months 11 days
Weighted average exercise price (in dollars per share)	$ 7.15
Aggregate intrinsic value	$ 0
Stock Options Exercisable [Abstract]
Shares (in shares)	0
Weighted average exercise price (in dollars per share)	$ 0
Aggregate intrinsic value	$ 0
8.2 to 10 [Member]
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 8.2
Range of exercise prices, maximum (in dollars per share)	$ 10
Stock Options Outstanding [Abstract]
Shares (in shares)	46,875
Average remaining contract life	4 years 5 months 8 days
Weighted average exercise price (in dollars per share)	$ 8.86
Aggregate intrinsic value	$ 0
Stock Options Exercisable [Abstract]
Shares (in shares)	9,375
Weighted average exercise price (in dollars per share)	$ 8.86
Aggregate intrinsic value	$ 0

GEOGRAPHIC INFORMATION AND EC45

GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	$ 13,680,107	$ 21,886,688	$ 25,949,769
Uganda [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	(1,122,400)	1,344,500
Mexico [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	123,200	(3,913,400)
EURODELTA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	(68,600)	972,500
Nigeria [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	(220,900)	287,500
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	(1,579,800)	(1,545,000)
Brazil [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	(5,340,250)	(2,111,700)
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	227,564	172,250	96,061
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	1,131,193	1,164,476	191,947
North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	5,082,319	6,525,951	11,134,691
South America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	4,875,087	10,350,812	12,429,717
Africa [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	2,363,944	3,673,199	$ 2,097,353
Middle East [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales-Year over Year	$ 55,300	$ 76,200

COMMITMENTS AND CONTINGENCIES46

COMMITMENTS AND CONTINGENCIES (Details)	12 Months Ended
	Dec. 31, 2016USD ($)KeyEmployee	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Employment Contracts [Abstract]
Number of key employees with whom Company has employment contracts | KeyEmployee	3
Aggregate annual salaries of employment contracts	$ 975,000
Contract one, expiration date	May 30, 2017
Contract two, expiration date	Mar. 31, 2019
Contract three, expiration date	Mar. 31, 2017
Future minimum salary commitments [Abstract]
2,017	$ 516,200
2,018	335,000
2,019	$ 55,800
Defined Contribution Plan Disclosure [Line Items]
Percentage of employer's matching contribution	40.00%
Expenses related to matching contribution	$ 96,051	$ 90,915	$ 82,750
Schedule of future minimum rental commitments [Abstract]
2,017	306,018
2,018	64,067
2,019	0
Total	370,085
Rent expense	516,708	511,900	476,000
Economic Dependency [Abstract]
Sales	13,680,107	21,886,688	25,949,769
Accounts Receivable	3,383,729	2,422,971
Accounts Payable	$ 1,437,290	1,260,520
Customer Concentration Risk [Member]
Economic Dependency [Abstract]
Concentration risk percentage	10.00%
Customer Concentration Risk [Member] | Customer 1 [Member]
Economic Dependency [Abstract]
Accounts Receivable	$ 828,848	775,209	6,230,886
Customer Concentration Risk [Member] | Customer 2 [Member]
Economic Dependency [Abstract]
Accounts Receivable	$ 0	700,656	386,270
Supplier Concentration Risk [Member]
Economic Dependency [Abstract]
Concentration risk percentage	10.00%
Supplier Concentration Risk [Member] | Vendor 1 [Member]
Economic Dependency [Abstract]
Accounts Payable	$ 26,984
Supplier Concentration Risk [Member] | Vendor 2 [Member]
Economic Dependency [Abstract]
Accounts Payable		$ 90,075	$ 200,855
Maximum [Member]
Defined Contribution Plan Disclosure [Line Items]
Employee contribution subject to employer matching contribution	5.00%
Employer matching contribution	2.00%
Medford [Member]
Entity Location [Line Items]
Monthly rent	$ 28,688
Lease expiration date	Apr. 30, 2017
Percentage of monthly rent increase in year three through five	2.50%
Holbrook [Member]
Entity Location [Line Items]
Monthly rent	$ 15,550
Lease expiration date	Apr. 30, 2018
Percentage of monthly rent increase in year three through five	3.00%
Sales [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]
Economic Dependency [Abstract]
Concentration risk percentage	35.00%	46.00%	47.00%
Sales	$ 4,801,577	$ 10,132,512	$ 12,253,526
Sales [Member] | Customer Concentration Risk [Member] | Customer 2 [Member]
Economic Dependency [Abstract]
Concentration risk percentage	13.00%	21.00%	26.00%
Sales	$ 1,796,477	$ 4,526,908	$ 6,618,251
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]
Economic Dependency [Abstract]
Concentration risk percentage	11.00%
Purchases	$ 652,273
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 2 [Member]
Economic Dependency [Abstract]
Concentration risk percentage		11.00%	14.00%
Purchases		$ 794,536	$ 1,331,647

COLLABORATIVE RESEARCH AND DE47

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS (Details) - USD ($)	1 Months Ended							12 Months Ended
	Sep. 30, 2016	Aug. 31, 2016	Feb. 29, 2016	Oct. 31, 2015	Jan. 31, 2015	Oct. 31, 2014	Feb. 28, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues from research and milestones								$ 3,739,049	$ 2,316,044	$ 1,672,258
Research and development expenses, excluding regulatory								6,900,000	5,400,000	4,100,000
BARDA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								472,700
Revenue from grants from inception								472,700
Maximum amount of development agreement		$ 5,933,742
BOVID [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								121,500
Maximum amount of development agreement	$ 669,423
Brain [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								297,000	469,600
Revenue from grants from inception								766,600
Maximum amount of development agreement					$ 946,000			350,000
TBS [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								65,000	205,000	0
Revenue from grants from inception								270,000
Maximum amount of development agreement						$ 320,000
Gates [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								0	307,000
Revenue from grants from inception								307,000
Maximum amount of development agreement					$ 307,000
SALIVA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								518,761
Maximum amount of development agreement			$ 677,944
Paul Allen [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								2,259,800	408,500
Revenue from grants from inception								2,668,265
Maximum amount of development agreement			$ 550,000	$ 2,118,265
RVR DENGUE [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								0	240,000	60,000
Revenue from grants from inception								300,000
Maximum amount of development agreement						$ 300,000
RVR TECH [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue earned from grant								0	$ 125,000	$ 1,125,000
Revenue from grants from inception								$ 1,250,000
Maximum amount of development agreement							$ 1,500,000

QUARTERLY FINANCIAL DATA (UNA48

QUARTERLY FINANCIAL DATA (UNAUDITED) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Selected Quarterly Financial Information [Abstract]
Total revenues	$ 4,254,876	$ 3,746,461	$ 3,266,405	$ 6,601,099	$ 4,420,816	$ 6,887,374	$ 6,716,158	$ 6,231,137	$ 17,868,841	$ 24,255,485	$ 27,645,284
Gross profit	1,753,386	1,952,097	1,580,305	3,165,548	1,870,543	2,910,534	3,019,132	2,686,618	$ 8,451,336	$ 10,486,827	$ 10,814,023
Net loss	$ (2,557,757)	$ (2,138,218)	$ (8,347,482)	$ (303,590)	$ (648,984)	$ (437,157)	$ (664,085)	$ (646,817)
Basic loss per share (in dollars per share)	$ (0.21)	$ (0.19)	$ (0.86)	$ (0.03)	$ (0.07)	$ (0.05)	$ (0.07)	$ (0.07)	$ (1.26)	$ (0.25)	$ (0.12)
Diluted loss per share (in dollars per share)	$ (0.21)	$ (0.19)	$ (0.86)	$ (0.03)	$ (0.07)	$ (0.05)	$ (0.07)	$ (0.07)	$ (1.26)	$ (0.25)	$ (0.12)

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]	Jan. 09, 2017USD ($)shares
Subsequent Event [Line Items]
Cash payment | $	$ 1,400,000
Shares issued (in shares) | shares	269,236
Shares held back (in shares) | shares	7,277
Monthly base salary | $	$ 10,000
Maximum [Member]
Subsequent Event [Line Items]
Cash milestone payment | $	$ 100,000
Stock milestone payment (in shares) | shares	21,830